Unprecedented Pandemic Turnaround in Uttar Pradesh with Dramatic Decline in Cases
The health authorities for the state of Uttar Pradesh are easing up on COVID-19-based restrictions, at least in zones of the state where SARS-CoV-2 infections now fall below 600 cases. The state was already offering ivermectin as part of a population-wide regimen but the health authorities there doubled down their efforts as India’s national COVID-19 guidelines introduced ivermectin just days before.
University of Minnesota ‘COVID-OUT’ Factorial Trial Investigates Potential of Ivermectin, Fluvoxamine & Metformin for Early Onset Mild-to-Moderate COVID-19
The University of Minnesota recently added generic study drugs to critically important yet not widely known clinical trial investigating outpatient treatment for SARS-CoV-2 infection, the virus behind COVID-19. The study, led by Carolyn Bramante called The COVIDOUT clinical trial targets an incredibly important segment of the COVID-19 diseases spectrum, which covers approximately 90% of the total cases that fall in either the asymptomatic or mild-to-moderate symptomatic category. At Present, there are no authorized treatments for this massive population. While a few pharmaceutical companies, such as Merck and Pfizer as well as AstraZeneca, are testing therapies that target this lucrative market, around the world other generic drugs are either under investigation or are in use such as Ivermectin, Favipiravir, and others.